| Medical and Health Sciences | 2021-2025 | 246 | CN 26 | 99.95 |
| Pediatrics, Perinatology and Child Health | Lifetime | 155 | CN 3 | 99.54 |
| Psychiatry and Mental health | Lifetime | 491 | CN 3 | 98.33 |
| Geriatrics and Gerontology | Lifetime | 116 | CN 3 | 97.17 |
| Emergency Medical Services | Lifetime | 511 | CN 7 | 95.19 |
| Toxicology | Lifetime | 251 | CN 2 | 86.84 |
| Ophthalmology | Lifetime | 864 | CN 26 | 69.55 |
| Infectious Diseases | 2021-2025 | 92 | CN 16 | 98.52 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 291 | CN 6 | 97.44 |
| Psychiatry and Mental health | 2021-2025 | 176 | CN 6 | 96.53 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 220 | CN 4 | 96.04 |
| Epidemiology | 2021-2025 | 533 | CN 59 | 95.15 |
| Surgery | 2021-2025 | 571 | CN 52 | 95.22 |
| Pediatrics, Perinatology and Child Health | 2021-2025 | 379 | CN 16 | 91.47 |
| Clinical Neurology | 2021-2025 | 277 | CN 12 | 91.64 |
| Clinical Psychology | 2021-2025 | 725 | CN 25 | 92.39 |
| Public, Environmental and Occupational Health | 2021-2025 | 949 | CN 53 | 90.23 |
| Oncology | 2021-2025 | 958 | CN 122 | 82.67 |
| Pharmaceutical studies and practices | Lifetime | 16 | CN 1 | 99.63 |
| Pharmaceutical Practices and Patient Outcomes | Lifetime | 27 | CN 1 | 99.38 |
| Child and Adolescent Health | Lifetime | 52 | CN 1 | 99.12 |
| Pharmacovigilance and Adverse Drug Reactions | Lifetime | 18 | CN 1 | 98.69 |
| COVID-19 Clinical Research Studies | Lifetime | 361 | CN 54 | 98.47 |
| Long-Term Effects of COVID-19 | Lifetime | 283 | CN 19 | 97.60 |
| Pharmacological Effects and Toxicity Studies | Lifetime | 254 | CN 3 | 98.55 |
| Attention Deficit Hyperactivity Disorder | Lifetime | 189 | CN 1 | 98.47 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 595 | CN 90 | 98.08 |
| COVID-19 and healthcare impacts | Lifetime | 304 | CN 10 | 95.97 |
| Patient Safety and Medication Errors | Lifetime | 116 | CN 1 | 98.14 |
| Epilepsy research and treatment | Lifetime | 560 | CN 3 | 97.65 |
| Pediatric Pain Management Techniques | Lifetime | 553 | CN 10 | 94.55 |
| Pharmaceutical Economics and Policy | Lifetime | 785 | CN 10 | 92.34 |
| Safe Handling of Antineoplastic Drugs | Lifetime | 491 | CN 5 | 70.78 |
| COVID-19 Clinical Research Studies | 2021-2025 | 134 | CN 17 | 99.24 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 198 | CN 31 | 99.09 |
| COVID-19 and healthcare impacts | 2021-2025 | 96 | CN 2 | 97.62 |
| Long-Term Effects of COVID-19 | 2021-2025 | 157 | CN 6 | 98.10 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 222 | CN 13 | 96.16 |
| COVID-19 and Mental Health | 2021-2025 | 554 | CN 62 | 95.42 |
| Viral Infections and Immunology Research | 2021-2025 | 217 | CN 49 | 92.22 |
| Attention Deficit Hyperactivity Disorder | 2021-2025 | 162 | CN 9 | 93.80 |
| Chronic Disease Management Strategies | 2021-2025 | 276 | CN 22 | 92.61 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 57 | CN 5 | 92.80 |
| Vaccine Coverage and Hesitancy | 2021-2025 | 664 | CN 56 | 92.48 |
| Pharmaceutical studies and practices | 2021-2025 | 239 | CN 5 | 88.49 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 624 | CN 44 | 89.56 |
| Pharmaceutical Practices and Patient Outcomes | 2021-2025 | 587 | CN 11 | 88.12 |
| Bone health and osteoporosis research | 2021-2025 | 473 | CN 48 | 86.47 |
| Bipolar Disorder and Treatment | 2021-2025 | 547 | CN 37 | 86.54 |
| Hip and Femur Fractures | 2021-2025 | 798 | CN 95 | 86.13 |
| Pharmacovigilance and Adverse Drug Reactions | 2021-2025 | 145 | CN 23 | 83.63 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 906 | CN 203 | 84.46 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 900 | CN 81 | 83.35 |
| Pharmaceutical Economics and Policy | 2021-2025 | 425 | CN 17 | 82.56 |
| Diabetes Management and Education | 2021-2025 | 933 | CN 44 | 73.28 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 995 | CN 59 | 71.65 |
| Potassium and Related Disorders | 2021-2025 | 546 | CN 17 | 65.96 |